Bioactive chemical compounds are versatile tools to analyze cellular signaling pathways as well as molecular mechanisms and may serve as effective pharmaceutical intervention in a clinical setting. However, screening a library of chemical compounds requires technologies not generally accessible to cell biology laboratories.
To close this gap IBCII has built up a phenotypic screening platform providing microscopy-based and live-cell screening technologies, which enable the identification of biological vulnerabilities and the phenotypic characterization of compound mode-of-action. On the basis of collaboration, the platform supports both internal as well as external researchers with expertise on and execution of phenotypic screens to monitor biological processes and their alteration over time via different readouts, including cell growth, morphological changes, and fluorescence. The set-up is compatible with high-throughput screens and thereby allows to combine phenotypic and chemical screening using targeted chemical compound libraries, siRNAs, or project specific stresses/treatments.
The phenotypic screening platform is closely connected to several research networks, including the CRC1177 on autophagy, ENABLE, PROXIDRUGS and the Innovative Medicine Initiative EUbOPEN.
Any requests for collaborations can be addressed to Alexandra Stolz or submitted via the submission portal.
For submission portal registration please contact Alexandra Stolz
To book time on the instruments please go to the BMLS scheduler. If you need an account, please contact David Krause
IT System Administrator
Networks & Servers Administration
Web & Databases Development
IT Systems Security
Sara was studying Biotechnology at the University Francisco de Vitoria, Spain and joined the Stolz lab in September 2020 for her Bachelor thesis on the impact of kinase signaling comparing 2D vs. 3D cultured cells. After finishing her Bachelor, Sara stayed in the lab as a research assistant and Lab Manager with a focus on cellular screens.